The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 1,169 | 5,425 | 1,119 | 23,895 |
| Depreciation and amortization | 21,792 | 23,146 | 21,431 | 40,641 |
| Loss on extinguishment of debt | - | 0 | 0 | - |
| Amortization of debt issuance costs and discounts | 462 | 454 | 445 | 869 |
| Non-cash operating lease expense | 925 | 944 | 998 | 2,065 |
| Stock-based compensation expense | 16,509 | 17,919 | 18,118 | 40,589 |
| Deferred income taxes | 4,069 | 11,982 | 8,089 | - |
| Loss on operating lease asset | 0 | 0 | 0 | 4,409 |
| Loss on disposal of capitalized software | - | 0 | - | - |
| Loss on minority equity interest investment | - | 0 | - | - |
| Other | 798 | 1,334 | 20 | 456 |
| Accounts receivable | -3,025 | 30,212 | 14,711 | 43,093 |
| Prescription reimbursement assets | 655,199 | 75,387 | - | - |
| Prepaid expenses and other assets | -2,177 | -14,846 | 7,437 | 15,796 |
| Accounts payable | -4,945 | -10,522 | 3,539 | 11,086 |
| Prescription reimbursement liabilities | 620,839 | 114,341 | - | - |
| Accrued expenses and other current liabilities | 1,744 | -41,023 | 45,443 | -3,235 |
| Operating lease liabilities | -1,478 | -1,537 | -1,545 | -3,187 |
| Other liabilities | -49 | 1,178 | 514 | 294 |
| Net cash provided by operating activities | 11,838 | 32,888 | 76,023 | 58,993 |
| Purchase of property and equipment | 1,136 | 1,241 | 1,748 | 532 |
| Acquisition | 0 | 13,440 | 0 | 30,000 |
| Capitalized software | 20,508 | 14,589 | 16,251 | 39,659 |
| Other | - | 2,500 | - | - |
| Net cash used in investing activities | -21,644 | -31,770 | -17,999 | -70,191 |
| Proceeds from long-term debt | - | 0 | 0 | - |
| Payments on long-term debt | 1,250 | 1,250 | 1,250 | 2,500 |
| Payments of debt issuance costs | - | 0 | 0 | - |
| Proceeds from employee stock purchase plan | - | 448 | 0 | 860 |
| Repurchases of class a common stock | 12,567 | 9,430 | 61,054 | 145,888 |
| Proceeds from exercise of stock options | 95 | 0 | 58 | 3 |
| Employee taxes paid related to net share settlement of equity awards | 2,582 | 2,595 | 3,567 | 8,305 |
| Net cash used in financing activities | -16,304 | -12,827 | -65,813 | -155,830 |
| Net change in cash and cash equivalents | -26,110 | -11,709 | -7,789 | -167,028 |
| Beginning of period | 261,820 | 174,817 | 448,346 | - |
| End of period | 235,710 | -11,709 | 273,529 | - |
GoodRx Holdings, Inc. (GDRX)
GoodRx Holdings, Inc. (GDRX)